Pharsight

Drug patents revoked in 2019

Drug patents revoked in 2019 at the European Patent Office (EPO).

Patent Number Patent Title Company Revoked Date Oppositions
EP1956014B1 Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same TEIJIN PHARMA LTD Dec, 2019
(Expiration: Jun, 2019)
DR SCHN
EP2874647B1 Method of diagnosis and treatment of metastatic cancer LA TROBE UNIVERSITY Dec, 2019
(Expiration: Jul, 2033)
GRUND
EP2574166B1 Cosmetics comprising cosmetic composition-impregnated urethane foam AMOREPACIFIC CORP Dec, 2019
(Expiration: Mar, 2032)
COSMAX
EP2025318B1 Two-phase composition for conditioning hair KAO GERMANY GMBH Dec, 2019
(Expiration: Aug, 2028)
HENKEL
EP2882454B1 Combination therapy for the treatment of glioblastoma F HOFFMANN LA ROCHE AG Dec, 2019
(Expiration: Aug, 2033)
DRRIES
NEUEFEIND
PFIZER
EP3046590B1 Method for producing a liquid pharmaceutical preparation SANOCHEMIA PHARMAZEUTIKA AG Dec, 2019
(Expiration: Jun, 2035)
GUERBET
EP3214091B1 Use of chimeric antigen receptor-modified t cells to treat cancer UNIVERSITY OF PENNSYLVANIA PENN Dec, 2019
(Expiration: Dec, 2031)
CABINET PLASSERAUD
MDECINS DU MONDE ET AL
MILTENYI BIOTEC
PUBLIC EYE
EP3094331B1 Combination-based treatment method NEKTAR THERAPEUTICS Dec, 2019
(Expiration: Jan, 2035)
IPSEN BIOPHARM
EP2759294B1 Formulation for percutaneous administration containing Fentanyl and analague thereof SAMYANG BIOPHARMACEUTICALS CORP Dec, 2019
(Expiration: Sep, 2032)
HEXAL
EP2852371B1 Cosmetic compositions comprising magnetosomes and uses thereof NATURA BISSE INTERNATIONAL SA Dec, 2019
(Expiration: May, 2033)
WITTOP KONING
EP2554168B1 Controlled release pharmaceutical composition ASTELLAS PHARMA INC Dec, 2019
(Expiration: Mar, 2031)
ALFRED E TIEFENBACHER
HEXAL
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
STADA ARZNEIMITTEL
EP1848422B1 Method for decreasing cartilage damage in dogs HILLS PET NUTRITION INC Dec, 2019
(Expiration: Feb, 2026)
IAMS EUROPE
MARS
EP2051694B1 Pharmaceutical compositions comprising aripiprazole NOBEL ILAC SANAYII VE TICARET AS Dec, 2019
(Expiration: Aug, 2027)
MULLEN
EP2216028B1 Immunostimulation by chemically modified single-stranded RNA CUREVAC AG Dec, 2019
(Expiration: Jul, 2023)
ETHERNA IMMUNOTHERAPIES
SCHNAPPAUF
STRAWMAN
EP2994125B1 Nintedanib zur anwendung in der behandlung von nsclc BOEHRINGER INGELHEIM INTERNATIONAL GMBH Dec, 2019
(Expiration: May, 2034)
DEXCEL PHARMA
GENERICS UK
HGF
TEVA PHARMACEUTICAL INDUSTRIES
EP2608784B1 Treatment or prevention of heart failure in a mammal receiving anti-coagulant therapy NOVARTIS AG Dec, 2019
(Expiration: Aug, 2031)
ALFRED E TIEFENBACHER
GENERICS UK
ZENTIVA
EP1711162B1 Composition for use in the local treatment of oropharyngeal conditions comprising ibuprofen or ketoprofen INDIVIDUAL Nov, 2019
(Expiration: Feb, 2025)
SANOFI
EP2311492B1 Antibody-containing stabilized preparations CHUGAI PHARMACEUTICAL CO LTD Nov, 2019
(Expiration: Aug, 2021)
MATHYS & SQUIRE
EP2645878B1 Prevention or treatment of overweight and obesity in type 2 diabetic patients NUTRICIA NV Nov, 2019
(Expiration: Dec, 2031)
FRESENIUS KABI DEUTSCHLAND
EP3019146B1 Long-wear cosmetic composition LOREAL SA Nov, 2019
(Expiration: Jul, 2034)
HENKEL
EP2758027B1 Perfume COTY INC Nov, 2019
(Expiration: Jun, 2032)
HENKEL
EP2682388B1 Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof MYLAN LABORATORIES LTD Nov, 2019
(Expiration: Jun, 2029)
HOEFER & PARTNER PATENTANWLTE MBB
LES LABORATOIRES SERVIER
EP2694043B1 Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder OTSUKA PHARMACEUTICAL CO LTD Nov, 2019
(Expiration: Apr, 2032)
ALFRED E TIEFENBACHER
GENERICS UK
EP2839826B1 Octocrylene-free sunscreen BEIERSDORF AG Nov, 2019
(Expiration: Jun, 2034)
BAYER BAYER CONSUMER CARE
LOREAL
EP2964675B1 Engager cells for immunotherapy BAYLOR COLLEGE OF MEDICINE Nov, 2019
(Expiration: Mar, 2034)
SCHLICH
EP2269603B1 Treatment of breast tumors with a rapamycin derivative in combination with exemestane NOVARTIS PHARMA GMBH Oct, 2019
(Expiration: Feb, 2022)
ACTAVIS PTC EHF
ETHYPHARM
GENERICS UK
INTAS PHARMACEUTICALS
STADA ARZNEIMITTEL
SYNTHON
TEVA PHARMACEUTICALS
WITTKOPP
ZENTIVA FRANCE
EP2661492B1 Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells JOHNS HOPKINS UNIVERSITY Oct, 2019
(Expiration: Jan, 2032)
I P S SERVICES
EP3021820B1 Antiperspirant spray devices and compositions PROCTER AND GAMBLE CO Oct, 2019
(Expiration: Jul, 2034)
BEIERSDORF
EP2899193B1 Crystalline form of abacavir that is essentially free of solvent ESTEVE QUIMICA SA Oct, 2019
(Expiration: Jan, 2029)
D YOUNG
FRKELLY
HAMM&WITTKOPP PATENTANWLTE PARTMBB
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
TER MEER STEINMEISTER & PARTNER PATENTANWLTE MBB
EP1955602B1 Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases NESTEC SA Oct, 2019
(Expiration: Sep, 2023)
ABBOTT LABORATORIES
EP2307058B1 Glycerophospholipids for the improvement of cognitive functions ENZYMOTEC LTD Oct, 2019
(Expiration: Jun, 2029)
NUTRICIA
EP3016630B1 Cosmetic composition comprising liquid fatty esters, volatile oils and thickeners, and cosmetic treatment processes LOREAL SA Oct, 2019
(Expiration: Jul, 2034)
HENKEL
EP2869706B1 Method for producing a protein comprising composition with reduced digestive coagulation NUTRICIA NV Oct, 2019
(Expiration: Jul, 2033)
NESTEC
EP2560662B1 Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved ALFA WASSERMAN SPA Oct, 2019
(Expiration: Apr, 2031)
BOTTI & FERRARI
GENERICS UK
EP2866777B1 Reducing composition comprising at least one sulfur-containing reducing agent, at least one fatty substance, at least one cationic surfactant and at least one oxyethylenated nonionic surfactant LOREAL SA Oct, 2019
(Expiration: Jun, 2033)
HENKEL
EP2429507B1 Phosphate-free pharmaceutical composition for the treatment of glaucoma URSAPHARM ARZNEIMITTEL GMBH Oct, 2019
(Expiration: May, 2030)
PHARMA STULLN
EP2701689B1 Pharmaceutical compositions of raltegravir, methods of preparation and use thereof HETERO RESEARCH FOUNDATION Oct, 2019
(Expiration: Apr, 2032)
GILL JENNINGS & EVERY
TER MEER STEINMEISTER & PARTNER PATENTANWLTE MBB
EP2943081B1 Nutritional compositions containing magnesium threonate and uses thereof MJN US HOLDINGS LLC Oct, 2019
(Expiration: Dec, 2033)
NESTEC
EP1800659B1 Cosmetic composition comprising at least one cationic polyvinyllactam, at least one fatty alcohol and at least one polyol, method for treatment of keratin fibres and use LOREAL SA Oct, 2019
(Expiration: Dec, 2026)
KAO GERMANY
EP2234584B1 Composition comprising an alkanolamine, a basic amino acid and a suitably selected additional alkaline agent LOREAL SA Sep, 2019
(Expiration: Dec, 2028)
HENKEL
EP2376052B1 Inorganic gel and composition and process for the production thereof BEIERSDORF AG Sep, 2019
(Expiration: Dec, 2029)
THE PROCTER & GAMBLE
EP1710259B1 Cosmetic composition thickened with an inverse latex SOCIETE DEXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC SA Sep, 2019
(Expiration: Jan, 2019)
SNF
EP2802646B1 Modified bordetella pertussis strains BIONET-ASIA CO LTD Sep, 2019
(Expiration: Dec, 2032)
GLAXO SMITHKLINE BIOLOGICALS
EP2805716B1 A pharmaceutical composition comprising buprenorphine having a rapid action OREXO AB Sep, 2019
(Expiration: Sep, 2019)
PATENTANWALTSKANZLEI CARTAGENA PARTNERSCHAFTSGESELLSCHAFT KLEMENT
EP2266531B1 Cosmetic composition comprising a superabsorbent polymer and an organic UV filter LOREAL SA Sep, 2019
(Expiration: Jun, 2030)
THE PROCTER & GAMBLE
EP2827830B1 Preservative composition and cosmetic products containing same HENKEL AG AND CO KGAA Sep, 2019
(Expiration: Nov, 2032)
BEIERSDORF
EP2194957B1 Composition comprising at least one ammonium salt, aqueous ammonia and at least one amino acid LOREAL SA Sep, 2019
(Expiration: Oct, 2028)
HENKEL
EP2736481B1 Method of removing colour from oxidatively dyed hair PERACHEM LTD Sep, 2019
(Expiration: Jul, 2032)
HENKEL
EP2560606B1 Colouring composition KAO GERMANY GMBH Sep, 2019
(Expiration: Apr, 2031)
LOREAL
EP2455062B1 Skin cleanser/hand cleaners comprising hydrophilic emollients and abrasives DEB IP LTD Sep, 2019
(Expiration: Apr, 2028)
HENKEL
EP2800567B1 An inhaler comprising a tiotropium-containing-composition TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC Sep, 2019
(Expiration: Dec, 2032)
M UNITED KINGDOM
EP2037965B1 Pharmaceutical composition with synergistic anticonvulsant effect UCB PHARMA GMBH Sep, 2019
(Expiration: Jun, 2027)
ACCORD HEALTHCARE
EP2560608B1 Colouring composition KAO GERMANY GMBH Sep, 2019
(Expiration: Apr, 2031)
HENKEL
EP2931741B1 Porcine parvovirus 5a, methods of use and vaccine BOEHRINGER INGELHEIM VETMEDICA INC Sep, 2019
(Expiration: Jan, 2034)
INTERVET
EP2214677B1 Compositions for the treatment of inflammation of the gastrointestinal tract MERITAGE PHARMA INC Sep, 2019
(Expiration: Nov, 2028)
DR FALK PHARMA
EP2558092B1 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer NOVARTIS AG Aug, 2019
(Expiration: Apr, 2031)
GENERICS UK
EP1589109B1 VMP-like sequences of pathogenic borrelia UNIVERSITY OF TEXAS SYSTEM Jul, 2019
(Expiration: Feb, 2017)
MIKROGEN
EP2618833B1 Breast cancer therapeutics IMBA INSTITUT FUR MOLEKULARE BIOTECHONOLOGIE GMBH Jul, 2019
(Expiration: Sep, 2031)
DEHMEL & BETTENHAUSEN PATENTANWLTE PARTMBB
PATENTANWLTE ISENBRUCK BSL HRSCHLER PARTG MBB
EP2643322B1 Salts and crystalline forms of an apoptosis-inducing agent ABBVIE INC Jul, 2019
(Expiration: Nov, 2031)
GENERICS UK
EP2568968B1 Manufacturing of active-free granules and tablets comprising the same EURO CELTIQUE SA Jul, 2019
(Expiration: May, 2031)
HERTIN UND PARTNER RECHTS UND PATENTANWLTE PARTG MBB
EP2907522B1 Method of increasing bone toughness and stiffness and reducing fractures ELI LILLY AND CO Jul, 2019
(Expiration: Aug, 2019)
GEDEON RICHTER RICHTER HELM BIOLOGICS RICHTER HELM BIOTEC
STADA ARZNEIMITTEL
TEVA PHARMACEUTICAL INDUSTRIES
EP2119426B1 Personal care compositions and methods COLGATE PALMOLIVE CO Jul, 2019
(Expiration: Dec, 2024)
KAO GERMANY
EP1589951B1 Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics SUPERNUS PHARMACEUTICALS INC Jun, 2019
(Expiration: Jan, 2024)
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
EP2934515B1 A pharmaceutical combination comprising binimetinib NOVARTIS AG Jun, 2019
(Expiration: Dec, 2033)
FRESENIUS KABI DEUTSCHLAND
EP2663278B1 Cosmetic cleaning agent HENKEL AG AND CO KGAA Jun, 2019
(Expiration: Dec, 2031)
LORAL
EP2699091B1 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds DEUTERX LLC Jun, 2019
(Expiration: Mar, 2032)
JOHNSON
EP2646470B1 Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier F HOFFMANN LA ROCHE AG Jun, 2019
(Expiration: Nov, 2031)
EIP
PFIZER
SANOFI
EP2266958B1 Antiviral agent SHIONOGI AND CO LTD Jun, 2019
(Expiration: Aug, 2022)
MERCK
EP1798285B1 Methods and medicament for inhibition the expression of a defined gene ALNYLAM EUROPE AG Jun, 2019
(Expiration: Jan, 2020)
SILENCE THERAPEUTICS
EP2882498B1 Agent and method for the temporary deformation of keratin fibres HENKEL AG AND CO KGAA Jun, 2019
(Expiration: Jul, 2033)
LOREAL
EP2198831B1 Method for lightening, lightening direct dyeing or oxidation dyeing carried out in the presence of an organic amine and a mineral base; suitable kit LOREAL SA May, 2019
(Expiration: Dec, 2029)
HENKEL
EP2981509B1 High-strength, translucent mg-high quartz mixed crystal glass ceramics SIRONA DENTAL SYSTEMS GMBH May, 2019
(Expiration: Mar, 2034)
IVOCLAR VIVADENT
EP2440232B1 Glycomacropeptide medical foods for nutritional management of phenylketonuria and other metabolic disorders WISCONSIN ALUMNI RESEARCH FOUNDATION Apr, 2019
(Expiration: Jun, 2030)
NEUEFEIND
NUTRICIA
EP3045182B1 Antagonist antibodies directed against calcitonin gene-related peptide for treating cluster headache TEVA PHARMACEUTICALS INTERNATIONAL GMBH Apr, 2019
(Expiration: Nov, 2026)
BREUER
ELI LILLY
EP2753190B1 Use of infant formula with cholesterol NUTRICIA NV Apr, 2019
(Expiration: Sep, 2032)
NESTEC
EP2234628B1 Compositions and methods of promoting wound healing CLEVELAND CLINIC FOUNDATION Apr, 2019
(Expiration: Dec, 2028)
DEHNS
EP2665463B1 Antiperspirant stick with improved long-term stability HENKEL AG AND CO KGAA Apr, 2019
(Expiration: Jan, 2032)
THE PROCTER & GAMBLE
EP2701713B1 Modulation of apolipoprotein ciii (apociii) expression IONIS PHARMACEUTICALS INC Apr, 2019
(Expiration: Apr, 2032)
PFIZER
STRAWMAN
EP2934464B1 Personal care compositions comprising anionic surfactants and hydrophobic actives DOW GLOBAL TECHNOLOGIES LLC Apr, 2019
(Expiration: Jan, 2034)
FIRMENICH
FLAVORS & FRAGRANCES
GIVAUDAN
EP2313073B1 Non-sulfate mild surfactant system for skin and hair cleaning HENKEL AG AND CO KGAA Apr, 2019
(Expiration: Jul, 2029)
BEIERSDORF
LOREAL
THE PROCTER & GAMBLE
EP2908835B1 Stable formulations MONTERO GIDA SANAYI VE TICARET AS Apr, 2019
(Expiration: Oct, 2033)
DR WILLMAR SCHWABE
EP3050882B1 Piperidin-4-yl azetidine derivatives as jak1 inhibitors INCYTE HOLDINGS CORP Apr, 2019
(Expiration: Mar, 2031)
GENERICS UK
EP3157932B1 Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5]pyrazino [2, 1-b]oxazepin-8-olate GILEAD SCIENCES INC Mar, 2019
(Expiration: Jun, 2035)
COOKE
EP2496700B1 Nucleic acid-containing lipid particles and related methods UNIVERSITY OF BRITISH COLUMBIA Mar, 2019
(Expiration: Nov, 2030)
MERCK SHARP & DOHME
WITHERS & ROGERS
EP2558435B1 Orthorhombic crystalline ingenol mebutate LEO PHARMA AS Mar, 2019
(Expiration: Apr, 2031)
GENERICS UK
TEVA PHARMACEUTICAL INDUSTRIES
EP2198843B1 Lightening of human keratinic fibers with a anhydrous composition comprising a mixture of monoethanolamine/basic amine acid and kit LOREAL SA Feb, 2019
(Expiration: Dec, 2029)
HENKEL
EP3000810B1 N3 alkylated benzimidazole derivative as mek inhibitor ARRAY BIOPHARMA INC Feb, 2019
(Expiration: Mar, 2023)
GENERICS UK TRADING MYLAN
EP2529622B1 Inhibitors of bruton's tyrosine kinase PHARMACYCLICS LLC Feb, 2019
(Expiration: Dec, 2026)
GENERICS UK
EP1885203B1 Methods for promoting health or wellness in adult animals HILLS PET NUTRITION INC Feb, 2019
(Expiration: May, 2026)
GEVERS PATENTS
MARS
EP2249775B1 Topical antimicrobial compositions RECKITT BENCKISER LLC Feb, 2019
(Expiration: Feb, 2029)
HENKEL
EP2265248B1 Use of one or more salts of glycyrrhizic acid for reducing the irritating action of surfactants in cosmetic compositions GIULIANI SPA Feb, 2019
(Expiration: Mar, 2029)
BEIERSDORF
EP2120568B1 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders CELATOR PHARMACEUTICALS INC Feb, 2019
(Expiration: Feb, 2028)
GENERICS UK
TEVA PHARMACEUTICAL INDUSTRIES
EP2227215B1 Compositions containing a solvated active agent suitable for dispensing as a compressed gas aerosol SC JOHNSON AND SON INC Feb, 2019
(Expiration: Jun, 2029)
THE PROCTER & GAMBLE
EP2734210B1 Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract ABBOTT LABORATORIES Jan, 2019
(Expiration: Jul, 2032)
FRESENIUS KABI DEUTSCHLAND
NUTRICIA